Drug updated on 4/17/2024
| Dosage Form | Injection (intramuscular: 0.2 mg/kg, 0.4 mg/kg) |
| Drug Class | Recombinant adenosine deaminases |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- To treat adenosine deaminase severe combined immunity deficiency (ADA-SCID) in pediatric and adult patients.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Revcovi (elapegademase-lvlr) Prescribing Information. | 2020 | Chiesi USA, Inc. Cary, NC |